OK, a long day indeed, and let me conclude with a what if
Suppose Ian Clark is not added onto DNDN BOD for the purpose of a Provenge ROW partnership but for something else rather, such as Nuevenge or TRP-P8 or CEA. The stock prospect is even brighter if that is the case. But one has to have the patience to hold for very long to benefit financially. With or without an immediate Provenge ROW partnership, DNDN will be a success and I have a very patient and long vision for holding it, despite being shaken out a couple of times in the past. Weak hand no more.
Suppose Ian Clark is not added onto DNDN BOD for the purpose of a Provenge ROW partnership but for something else rather, such as Nuevenge or TRP-P8 or CEA. The stock prospect is even brighter if that is the case. But one has to have the patience to hold for very long to benefit financially. With or without an immediate Provenge ROW partnership, DNDN will be a success and I have a very patient and long vision for holding it, despite being shaken out a couple of times in the past. Weak hand no more.